Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting 0% beneficial ownership of Procter & Gamble Co common stock and an amount beneficially owned of 0 shares. The filing states this follows an internal realignment: certain Vanguard subsidiaries or business divisions will report ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is a disclosure of ownership structure changes and notes that the disaggregated entities pursue the same investment strategies previously followed by The Vanguard Group, Inc.
PROCTER & GAMBLE Co director Portman Robert Jones reported an amended equity award. The Form 4/A corrects a prior filing that had shown a grant of 193 restricted stock units under the company’s 2025 Stock and Incentive Compensation Plan; the amended report shows an award of 49 RSUs instead. Following this compensation-related acquisition, his directly held common stock position is 5,065.7148 shares, making the change administrative rather than a new trading decision.
Portman Robert Jones reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Robert Jones Portman received an equity award of 193 shares of Common Stock on 2026-03-10.
The award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, including dividend equivalents in the form of additional units. Following this grant, he holds 5,209.7148 shares directly.
McEvoy Ashley reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Ashley McEvoy received an equity award of 161 shares of Common Stock on 2026-03-10. The transaction is coded as a grant or award, not an open-market purchase, with a price per share of $0.0000, indicating compensation rather than cash investment.
Footnotes explain that the award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and that the total includes dividend equivalents in the form of additional Restricted Stock Units. Following this grant, McEvoy directly holds 5,751.065 shares.
McCarthy Christine M reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Christine M. McCarthy received an award of 209 shares of Common Stock on March 10, 2026. The filing describes this as a grant or award transaction, with no cash price per share reported.
These shares are in the form of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. The total reported direct holdings after this award are 17,128.6365 shares, which include dividend equivalents granted as additional Restricted Stock Units.
Kempczinski Christopher J reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Christopher J. Kempczinski received an award of 201 shares of Common Stock as a grant under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. After this compensation-related award, his directly held stake increased to 11,251.4805 shares, including dividend-equivalent restricted stock units.
JIMENEZ JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Joseph Jimenez received a grant of 273 shares of Common Stock in the form of restricted stock units. The award was made at no cash price as part of The Procter & Gamble 2025 Stock and Incentive Compensation Plan and includes dividend equivalents credited as additional units. After this compensation-related grant, his directly held position reported in this filing increased to 36,512.1482 shares of Common Stock, showing this is a relatively small, routine addition to an existing stake rather than a market purchase or sale.
ARNOLD CRAIG reported acquisition or exercise transactions in this Form 4 filing.
Procter & Gamble director Craig Arnold received a grant of 161 shares of Common Stock through Restricted Stock Units under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. The award, which includes dividend equivalents in the form of additional Restricted Stock Units, increased his directly held position to 2,586.0624 shares.
PROCTER & GAMBLE Co executive Francisco Ma. Fatima, CEO of Baby, Fem & Family Care, reported multiple stock moves. On February 27, 2026, she completed open-market sales totaling 5,549 shares of common stock at prices around $165.29 to $165.32, leaving 1,028.739 directly held shares.
She also received a grant of 57.0033 Restricted Stock Units on February 17, 2026, bringing her direct RSU holdings to 888.7607 units. Footnotes explain these RSUs include dividend equivalents that will deliver in shares at retirement or as deferred compensation. Additional indirect common stock holdings are reported through retirement plans, a spouse, and a SLAT trust.
PROCTER & GAMBLE Co executive Susan Street Whaley reported both a stock sale and an equity award. On February 19, 2026, she completed an open-market sale of 1,809 shares of common stock at an average price of $159.4551 per share.
After this sale, her directly held common stock position was 30,215.0293 shares. She also had 6,589.6417 shares held indirectly through a retirement plan trustee. On February 17, 2026, she acquired 11.485 restricted stock units at no cost, increasing her RSU balance to 65.1290 units, which are scheduled to settle in Procter & Gamble common stock, generally in connection with retirement.